You are here:
Name SMC ID No Manufacturer Status Sub. Type
 
abiraterone (Zytiga) 764/12 Janssen-Cilag Ltd Not Recommended Full submission
abiraterone (Zytiga) 764/12 Janssen-Cilag Ltd Restricted Resubmission
abiraterone (Zytiga) 873/13 Janssen-Cilag Ltd Not Recommended Non submission
abiraterone (Zytiga) 873/13 Janssen-Cilag Ltd Accepted IRP
abiraterone (Zytiga) 873/13 Janssen-Cilag Ltd Not Recommended Full submission
afatinib (Giotrif) 1174/16 Boehringer Ingelheim Ltd Not Recommended Non submission
afatinib (Giotrif) 920/13 Boehringer Ingelheim Ltd Accepted Full submission
aflibercept (Zaltrap) 878/13 Sanofi-Aventis Not Recommended Full submission
aflibercept (Zaltrap) 878/13 Sanofi-Aventis Accepted Resubmission
alectinib hydrochloride (Alecensa) 1257/17 Roche Not Recommended Non submission
alemtuzumab (Lemtrada) 959/14 Genzyme Therapeutics Ltd Accepted Full submission
alemtuzumab (MabCampath) 494/08 Bayer plc/Bayer Schering Pharma Marketing Authorisation Withdrawn Full submission
Anastrozole (Arimidex®) 90/04 AstraZeneca UK Ltd Restricted Full submission
anastrozole 1mg tablet (Arimidex) 322/06 AstraZeneca UK Ltd Restricted Full submission
Anastrozole 1mg tablets (Arimidex®) 198/05 AstraZeneca UK Ltd Restricted Full submission
Avonex® liquid (Interferon beta 1a) 58/03 Biogen Idec Ltd Restricted Abbreviated Submission
axitinib (Inlyta) 855/13 Pfizer Ltd Not Recommended Full submission
axitinib (Inlyta) 855/13 Pfizer Ltd Accepted Resubmission
azacitidine (Vidaza) 589/09 Celgene Ltd Not Recommended Full submission
azacitidine (Vidaza) 589/09 Celgene Ltd Accepted Resubmission
azacitidine (Vidaza) 1175/16 Celgene Ltd Not Recommended Non submission
belatacept (Nulojix) 786/12 Bristol-Myers Squibb Pharmaceuticals Ltd Not Recommended Full submission
belimumab (Benlysta) 775/12 GlaxoSmithKline UK Ltd Not Recommended Full submission
bendamustine (Levact) 700/11 Napp Pharmaceuticals Ltd Not Recommended Non submission
bendamustine (Levact) 701/11 Napp Pharmaceuticals Ltd Not Recommended Non submission
bendamustine hydrochloride (Levact) 694/11 Napp Pharmaceuticals Ltd Accepted Full submission
bevacizumab (Avastin) 425/07 Roche Not Recommended Non submission
bevacizumab (Avastin) 459/08 Roche Superseded Non submission
bevacizumab (Avastin) 469/08 Roche Superseded Full submission
bevacizumab (Avastin) 778/12 Roche Not Recommended Full submission
bevacizumab (Avastin) 806/12 Roche Not Recommended Full submission
bevacizumab (Avastin) 806/12 Roche Not Recommended Resubmission
bevacizumab (Avastin) 806/12 Roche Restricted Resubmission
bevacizumab (Avastin) 853/13 Roche Not Recommended Full submission
bevacizumab (Avastin) 1135/16 Roche Accepted Full submission
bevacizumab (Avastin) 1190/16 Roche Not Recommended Non submission
bevacizumab (Avastin) 1063/15 Roche Restricted Full submission
bevacizumab (Avastin) 1275/17 Roche Not Recommended Non submission
Bevacizumab 100mg/4ml and 400mg/16ml solution for intravenous infusion (Avastin®) 221/05 Roche Not Recommended Full submission
Bevacizumab 100mg/4ml and 400mg/16ml solution for intravenous infusion (Avastin®) 221/05 Roche Not Recommended Resubmission
Bevacuzimab (Avastin) 387/07 Roche Not Recommended Non submission
Bexarotene (Targretin®) 14/02 Ligland/Elan Restricted Full submission
blinatumomab (Blincyto) 1145/16 Amgen Ltd Accepted Full submission
bortezomib (Velcade) 302/06 Ortho Biotech Accepted Resubmission
bortezomib (Velcade) 822/12 Janssen-Cilag Ltd Accepted Abbreviated Submission
bortezomib (Velcade) 1075/15 Janssen-Cilag Ltd Accepted Full submission
bortezomib (Velcade) 927/13 Janssen-Cilag Ltd Restricted Full submission
bortezomib (Velcade) 3.5mg powder for intravenous injection 302/06 Ortho Biotech Not Recommended Full submission
Bortezomib (Velcade®) 126/04 Ortho Biotech Accepted Full submission
bortezomib, 3.5mg vial of powder for solution for intravenous injection (Velcade) 302/06 Ortho Biotech Not Recommended Resubmission
bosutinib (Bosulif) 910/13 Pfizer Ltd Not Recommended Full submission
bosutinib (Bosulif) 910/13 Pfizer Ltd Accepted Resubmission
brentuximab vedotin (Adcetris) 845/12 Takeda UK Ltd Not Recommended Non submission
brentuximab vedotin (Adcetris) 845/12 Takeda UK Ltd Restricted Full submission
busulfan, 6mg/ml, intravenous (Busilvex) 337/06 Pierre Fabre Ltd Accepted Full submission
cabazitaxel (Jevtana) 735/11 Sanofi-Aventis Not Recommended Full submission
cabazitaxel (Jevtana) 735/11 Sanofi-Aventis Not Recommended Resubmission
cabazitaxel (Jevtana) 735/11 Sanofi-Aventis Restricted Resubmission
cabozantinib (Cabometyx) 1234/17 Ipsen Ltd Accepted Full submission
cabozantinib (Cometriq) 1022/15 Swedish Orphan Not Recommended Full submission
canakinumab (Ilaris) 658/10 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
canakinumab (Ilaris) 1210/16 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
canakinumab (Ilaris) 882/13 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
canakinumab (Ilaris) Arthritis 883/13 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
canakinumab (llaris) 926/13 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
capecitabine (Xeloda) 507/08 Roche Accepted Full submission
capecitabine (Xeloda) 716/11 Roche Accepted Full submission
Capecitabine (Xeloda®) 34/03 Roche Restricted Full submission
Capecitabine 150 and 500mg tablets (Xeloda®) 193/05 Roche Accepted Full submission
capecitabine 150mg and 500mg tablets (Xeloda) 401/07 Roche Accepted Full submission
carfilzomib (Kyprolis) 1171/16 Amgen Ltd Not Recommended Resubmission
carfilzomib (Kyprolis) 1242/17 Amgen Ltd Accepted Full submission
carfilzomib (Kyprolis) 1171/16 Amgen Ltd Not Recommended Full submission
Carmustine implant (Gliadel®) 215/05 Link Pharmaceuticals Ltd Accepted Full submission
catumaxomab (Removab) 788/12 Fresenius Medical Care (UK) Ltd Not Recommended Non submission
ceritinib (Zykadia) 1097/15 Novartis Pharmaceuticals UK Ltd Accepted Full submission
cetuximab (Erbitux) 155/05 Merck Serono Ltd Superseded IRP
cetuximab (Erbitux) 155/05 Merck Serono Ltd Superseded Full submission
cetuximab (Erbitux) 547/09 Merck Serono Ltd Not Recommended Non submission
cetuximab (Erbitux) 543/09 Merck Serono Ltd Superseded Full submission
cetuximab (Erbitux) 543/09 Merck Serono Ltd Superseded Resubmission
cetuximab (Erbitux) 1012/14 Merck Serono Ltd Superseded Full submission
cetuximab 2mg/ml intravenous infusion (Erbitux) 279/06 Merck KGaA Restricted Full submission
cladribine (LITAK) 537/09 LIPOMED GmbH Accepted Abbreviated Submission
clofarabine, 1mg/ml concentrate for solution for infusion (Evoltra) 327/06 Bioenvision Limited Restricted Full submission
cobimetinib (Cotellic) 1191/16 Roche Not Recommended Non submission
crizotinib (Xalkori) 865/13 Pfizer Ltd Not Recommended Full submission
crizotinib (Xalkori) 865/13 Pfizer Ltd Accepted Resubmission
crizotinib (Xalkori) 1152/16 Pfizer Ltd Accepted Full submission
dabrafenib (Tafinlar) 1023/15 GlaxoSmithKline UK Ltd Restricted Full submission
daclizumab (Zinbryta) 1216/17 Biogen Idec Ltd Restricted Full submission
daratumumab (Darzalex) 1205/17 Janssen-Cilag Ltd Not Recommended Full submission
daratumumab (Darzalex) 1205/17 Janssen-Cilag Ltd Restricted Resubmission
dasatinib (Sprycel) 1170/16 Bristol-Myers Squibb Pharmaceuticals Ltd Accepted Full submission
dasatinib (Sprycel) Second Line Treatment 370/07 Bristol-Myers Squibb Pharmaceuticals Ltd Accepted Resubmission
dasatinib 20mg, 50mg, 70mg tablets (Sprycel) 371/07 Bristol-Myers Squibb Pharmaceuticals Ltd Not Recommended Full submission
dasatinib 20mg, 50mg, 70mg tablets (Sprycel) 370/07 Bristol-Myers Squibb Pharmaceuticals Ltd Superseded Full submission
Decapeptyl SR 11.25 mg (Triptorelin acetate®) 109/04 Ipsen Ltd Accepted Abbreviated Submission
decitabine (Dacogen) 846/12 Janssen-Cilag Ltd Not Recommended Non submission
degarelix (Firmagon) 560/09 Ferring Pharmaceuticals Ltd Not Recommended Full submission
degarelix (Firmagon) 560/09 Ferring Pharmaceuticals Ltd Accepted Resubmission
dexrazoxane 20mg/ml, for infusion (Savene) 361/07 TopoTarget A/S Not Recommended Full submission
dexrazoxane (Cardioxane) 419/07 419/07 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
dexrazoxane (Savene) 361/07 TopoTarget A/S Not Recommended Resubmission
dimethyl fumarate (Tecfidera) 886/13 Biogen Idec Ltd Accepted Full submission
docetaxel (Taxotere) 481/08 Sanofi-Aventis Restricted Full submission
docetaxel (Taxotere) 659/10 Sanofi-Aventis Not Recommended Non submission
docetaxel (Taxotere) injection concentrate 333/06 Sanofi-Aventis Not Recommended Non submission
Docetaxel (Taxotere®) 42/03 Aventis Restricted Full submission
docetaxel 20 and mg concentrate and solvent for solution for infusion (Taxotere) 369/07 Sanofi-Aventis Restricted Full submission
Docetaxel 20mg, 80mg concentrate and solvent for solution for infusion, single dose vials (Taxotere®) 201/05 Sanofi-Aventis Accepted Full submission
Docetaxel concentrate and solvent for solution for infusion, single dose vials (Taxotere®) 209/05 Sanofi-Aventis Superseded Full submission
elotuzumab (Empliciti) 1183/16 Bristol-Myers Squibb Pharmaceuticals Ltd Not Recommended Non submission
eltrombopag (Revolade) 625/10 GlaxoSmithKline UK Ltd Restricted Full submission
enzalutamide (Xtandi) 1066/15 Astellas Pharma Ltd Accepted IRP
enzalutamide (Xtandi) 1066/15 Astellas Pharma Ltd Not Recommended Full submission
enzalutamide (Xtandi) 911/13 Astellas Pharma Ltd Accepted Full submission
eribulin (Halaven) 1065/15 Eisai Ltd Restricted Resubmission
eribulin (Halaven) 1065/15 Eisai Ltd Not Recommended Full submission
eribulin mesylate (Halaven) 726/11 Eisai Ltd Not Recommended Full submission
Erlotinib (Tarceva) 382/07 Roche Not Recommended Non submission
erlotinib (Tarceva) 664/10 Roche Not Recommended Full submission
erlotinib (Tarceva) 749/11 Roche Accepted Full submission
Erlotinib (Tarceva®) 220/05 Roche Superseded Resubmission
Erlotinib (Tarceva®) 220/05 Roche Not Recommended Full submission
everolimus (Afinitor) 595/10 Novartis Pharmaceuticals UK Ltd Not Recommended Full submission
everolimus (Afinitor) 872/13 Novartis Pharmaceuticals UK Ltd Accepted Resubmission
everolimus (Afinitor) 872/13 Novartis Pharmaceuticals UK Ltd Not Recommended Full submission
everolimus (Afinitor) 872/13 Novartis Pharmaceuticals UK Ltd Not Recommended Resubmission
everolimus (Afinitor) 777/12 Novartis Pharmaceuticals UK Ltd Superseded Full submission
everolimus (Afinitor) 1215/17 Novartis Pharmaceuticals UK Ltd Superseded Full submission
everolimus (Afintor) 595/10 Novartis Pharmaceuticals UK Ltd Accepted Resubmission
everolimus (Certican) 1117/15 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
everolimus (Certican) 1288/17 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
everolimus (Votubia) 787/12 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
everolimus (Votubia) 884/13 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
Exemestane 25mg tablets (Aromasin®) 210/05 Pfizer Ltd Superseded Full submission
fingolimod (Gilenya) 763/12 Novartis Pharmaceuticals UK Ltd Not Recommended Full submission
fingolimod (Gilenya) 763/12 Novartis Pharmaceuticals UK Ltd Restricted Resubmission
fingolimod (Gilenya) 992/14 Novartis Pharmaceuticals UK Ltd Restricted Full submission
fingolimod (Gilenya) 1038/15 Novartis Pharmaceuticals UK Ltd Accepted Full submission
fludarabine, 10mg tablet and 50mg for injection or infusion (Fludara) 176/05 Schering Health Care Ltd Restricted Full submission
follitropin delta (Rekovelle) 1269/17 Ferring Pharmaceuticals Ltd Not Recommended Non submission
fulvestrant (Faslodex) 114/04 AstraZeneca UK Ltd Accepted Resubmission
fulvestrant (Faslodex) 1294/17 AstraZeneca UK Ltd Not Recommended Non submission
Fulvestrant (Faslodex®) 114/04 AstraZeneca UK Ltd Not Recommended Full submission
gefitinib (Iressa) 615/10 AstraZeneca UK Ltd Not Recommended Full submission
gefitinib (Iressa) 615/10 AstraZeneca UK Ltd Not Recommended Resubmission
gefitinib (Iressa) 615/10 AstraZeneca UK Ltd Restricted Resubmission
gemcitabine 200mg and 1g powder for solution for infusion (Gemzar) 154/05 Eli Lilly and Company Ltd Restricted Resubmission
Gemcitabine/paclitaxel (Gemzar®) 154/05 Eli Lilly and Company Ltd Not Recommended Full submission
glatiramer acetate (Copaxone) 1108/15 Teva UK Limited Accepted Abbreviated Submission
Gonapeptyl depot 3.75mg 269/06 Ferring Pharmaceuticals Ltd Not Recommended Non submission
Gonapeptyl depot 3.75mg 270/06 Ferring Pharmaceuticals Ltd Not Recommended Non submission
histamine dihydrochloride (Ceplene) 666/10 Meda Pharmaceuticals Ltd Not Recommended Full submission
histrelin acetate (Vantas) 557/09 Orion Pharma (UK) Ltd Restricted Full submission
ibritumomab tiuxetan (Zevalin) 171/05 Schering Health Care Ltd Not Recommended Resubmission
Ibritumomab tiuxetan (Zevalin®) 171/05 Schering Health Care Ltd Not Recommended Full submission
ibritumomab tiuxetan 1.6mg/ml (Zevalin) 499/08 Bayer plc/Bayer Schering Pharma Not Recommended Non submission
ibrutinib (Imbruvica) 1151/16 Janssen-Cilag Ltd Restricted Resubmission
ibrutinib (Imbruvica) 1258/17 Janssen-Cilag Ltd Not Recommended Non submission
ibrutinib (Imbruvica) 1289/17 Janssen-Cilag Ltd Not Recommended Non submission
ibrutinib (Imbruvica) CLL 1151/16 Janssen-Cilag Ltd Restricted Full submission
ibrutinib (Imbruvica) MCL 1150/16 Janssen-Cilag Ltd Accepted Full submission
idelalisib (Zydelig) 1212/16 Gilead Sciences Ltd Not Recommended Non submission
idelalisib (Zydelig) 1026/15 Gilead Sciences Ltd Restricted Full submission
idelalisib (Zydelig) 1039/15 Gilead Sciences Ltd Accepted Full submission
imatinib (Glivec) 426/07 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
imatinib (Glivec) 427/07 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
imatinib (Glivec) 428/07 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
imatinib (Glivec) 429/07 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
imatinib (Glivec) 430/07 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
imatinib (Glivec) 584/09 Novartis Pharmaceuticals UK Ltd Restricted Resubmission
imatinib (Glivec) 584/09 Novartis Pharmaceuticals UK Ltd Restricted Resubmission
imatinib (Glivec) 584/09 Novartis Pharmaceuticals UK Ltd Not Recommended Full submission
imatinib (Glivec) 923/13 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
imatinib (Glivec) 01/02 Novartis Pharmaceuticals UK Ltd Superseded Full submission
Imatinib (Glivec®) 08/02 Novartis Pharmaceuticals UK Ltd Restricted Full submission
Imatinib (Glivec®) 26/02 Novartis Pharmaceuticals UK Ltd Restricted Full submission
interferon beta-1a (Rebif) 825/12 Merck Serono Ltd Not Recommended Non submission
Interferon beta-1b 250microgram/ml for solution for injection (Betaferon) 345/07 Schering Health Care Ltd Not Recommended Full submission
ipilimumab (Yervoy) 779/12 Bristol-Myers Squibb Pharmaceuticals Ltd Not Recommended Full submission
ipilimumab (Yervoy) 779/12 Bristol-Myers Squibb Pharmaceuticals Ltd Accepted Resubmission
ipilimumab (Yervoy) 997/14 Bristol-Myers Squibb Pharmaceuticals Ltd Accepted Full submission
Lanreotide (Somatuline® LA) 231/06 Ipsen Ltd Not Recommended Non submission
lapatinib (Tyverb) 526/09 GlaxoSmithKline UK Ltd Not Recommended Full submission
lapatinib (Tyverb) 526/09 GlaxoSmithKline UK Ltd Not Recommended Resubmission
lapatinib (Tyverb) 768/12 GlaxoSmithKline UK Ltd Superseded Non submission
lapatinib (Tyverb) 925/13 GlaxoSmithKline UK Ltd Not Recommended Non submission
lenalidomide (Revlimid) 441/08 Celgene Ltd Restricted Resubmission
lenalidomide (Revlimid) 441/08 Celgene Ltd Not Recommended Full submission
lenalidomide (Revlimid) 441/08 Celgene Ltd Restricted Resubmission
lenalidomide (Revlimid) 1211/16 Celgene Ltd Not Recommended Non submission
lenalidomide (Revlimid) 1096/15 Celgene Ltd Restricted Full submission
lenalidomide (Revlimid) 942/14 Celgene Ltd Accepted Full submission
lenvatinib (Lenvima) 1179/16 Eisai Ltd Accepted Full submission
letrozole (Femara) 251/06 Novartis Pharmaceuticals UK Ltd Restricted Full submission
Letrozole (Femara®) 152/05 Novartis Pharmaceuticals UK Ltd Restricted Full submission
liposomal cytarabine 50mg suspension for injection (DepoCyte) 164/05 Napp Pharmaceuticals Ltd Not Recommended Resubmission
liposomal cytarabine 50mg suspension for injection (Depocyte®) 164/05 Napp Pharmaceuticals Ltd Not Recommended Full submission
liposomal irinotecan (Onivyde) 1217/17 Shire Pharmaceuticals Not Recommended Full submission
mercaptopurine (Xaluprine) 798/12 Nova Laboratories Ltd Accepted Abbreviated Submission
mifamurtide (Mepact) 621/10 Takeda UK Ltd Not Recommended Full submission
mifamurtide (Mepact) 621/10 Takeda UK Ltd Accepted Resubmission
mitotane 500 mg tablets (Lysodren) 328/06 Laboratoire HRA Pharma Not Recommended Full submission
Mycophenolate sodium (Myfortic®) 144/04 Novartis Pharmaceuticals UK Ltd Accepted Full submission
natalizumab (Tysabri®) 979/14 Biogen Idec Ltd Not Recommended Non submission
natalizumab 300mg concentrate for solution for infusion (Tysabri) 329/06 Biogen Idec Ltd Not Recommended Full submission
natalizumab 300mg concentrate for solution for infusion (Tysabri) 329/06 Biogen Idec Ltd Restricted Resubmission
necitumumab (Portrazza) 1184/16 Eli Lilly and Company Ltd Not Recommended Non submission
nelarabine (Atriance) 454/08 GlaxoSmithKline UK Ltd Restricted Full submission
nilotinib (Tasigna) 440/08 Novartis Pharmaceuticals UK Ltd Superseded Full submission
nilotinib (Tasigna) 709/11 Novartis Pharmaceuticals UK Ltd Superseded Full submission
nintedanib (Ofev) 1076/15 Boehringer Ingelheim Ltd Restricted Full submission
nintedanib (Vargatef) 1027/15 Boehringer Ingelheim Ltd Accepted Full submission
nivolumab (Opdivo) 1120/16 Bristol-Myers Squibb Pharmaceuticals Ltd Not Recommended Full submission
nivolumab (Opdivo) 1120/16 Bristol-Myers Squibb Pharmaceuticals Ltd Restricted Resubmission
nivolumab (Opdivo) 1144/16 Bristol-Myers Squibb Pharmaceuticals Ltd Accepted Full submission
nivolumab (Opdivo) 1187/16 Bristol-Myers Squibb Pharmaceuticals Ltd Restricted Full submission
nivolumab (Opdivo) 1188/16 Bristol-Myers Squibb Pharmaceuticals Ltd Not Recommended Full submission
nivolumab (Opdivo) 1188/16 Bristol-Myers Squibb Pharmaceuticals Ltd Accepted Resubmission
nivolumab (Opdivo) (SCCHN) 1261/17 Bristol-Myers Squibb Pharmaceuticals Ltd Restricted Full submission
nivolumab (Opdivo) for cHL 1240/17 Bristol-Myers Squibb Pharmaceuticals Ltd Accepted Full submission
nivolumab (Opdivo) for non-squamous NSCLC 1180/16 Bristol-Myers Squibb Pharmaceuticals Ltd Restricted Full submission
nivolumab (Opvido) 1285/18 Bristol-Myers Squibb Pharmaceuticals Ltd Not Recommended Full submission
obinutuzumab (Gazyvaro) 1008/14 Roche Accepted Full submission
obinutuzumab (Gazyvaro) 1219/17 Roche Accepted Full submission
obinutuzumab (Gazyvaro) 1286/18 Roche Not Recommended Full submission
ofatumumab (Arzerra) 626/10 GlaxoSmithKline UK Ltd Not Recommended Full submission
ofatumumab (Arzerra) 1037/15 Novartis Pharmaceuticals UK Ltd Restricted Full submission
ofatumumab (Arzerra) 1237/17 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
olaparib (Lynparza) 1047/15 AstraZeneca UK Ltd Accepted Resubmission
olaparib (Lynparza) 1047/15 AstraZeneca UK Ltd Not Recommended Full submission
olaratumab (Lartruvo) 1273/17 Eli Lilly and Company Ltd Restricted Full submission
osimertinib (Tagrisso) 1214/17 AstraZeneca UK Ltd Restricted Full submission
Oxaliplatin 50mg, 100mg powder for intravenous infusion (Eloxatin®) 211/05 Sanofi-Aventis Accepted Full submission
paclitaxel (Abraxane) 556/09 Abraxis Bioscience Ltd Restricted Full submission
paclitaxel (Abraxane) 556/09 Abraxis Bioscience Ltd Not Recommended Non submission
paclitaxel albumin (Abraxane) 968/14 Celgene Ltd Accepted Resubmission
paclitaxel albumin (Abraxane) 1071/15 Celgene Ltd Not Recommended Non submission
paclitaxel albumin (Abraxane®) 968/14 Celgene Ltd Not Recommended Full submission
palbociclib (Ibrance) 1276/17 Pfizer Ltd Restricted Full submission
Palifermin (Kepivance®) 272/06 Amgen Ltd Not Recommended Non submission
panitumumab (Vectibix) 769/12 Amgen Ltd Superseded Non submission
panitumumab (Vectibix) 1082/15 Amgen Ltd Superseded Non submission
panitumumab 20mg/ml concentrate for solution for infusion (Vectibix) 486/08 Amgen Ltd Superseded Non submission
panobinostat (Farydak) 1122/16 Novartis Pharmaceuticals UK Ltd Accepted Full submission
pasireotide (as pamoate) (Signifor) 1048/15 Novartis Pharmaceuticals UK Ltd Accepted Full submission
pazopanib (Votrient) 676/11 GlaxoSmithKline UK Ltd Restricted Full submission
pazopanib (Votrient) 820/12 GlaxoSmithKline UK Ltd Not Recommended Full submission
pegaspargase (Oncaspar) 1197/16 Baxalta Accepted Abbreviated Submission
peginterferon alfa-2a (Pegasys) 561/09 Roche Superseded Full submission
peginterferon alfa-2a (Pegasys) 1312/18 Roche Not Recommended Non submission
peginterferon beta 1a (Plegridy) 1018/14 Biogen Idec Ltd Accepted Full submission
Pegylated interferon alfa 2a (Pegasys®) 186/05 Roche Accepted Full submission
pegylated interferon alfa 2b plus ribavirin (ViraferonPeg plus Rebetol) 488/08 Schering-Plough Ltd Superseded Full submission
pegylated interferon alfa-2a (Pegasys) 871/13 Roche Superseded Abbreviated Submission
Pegylated interferon alfa-2a (Pegasys®) 10/02 Roche Restricted Full submission
pegylated interferon alfa-2b (Viraferon Peg) 794/12 MSD Superseded Abbreviated Submission
Pegylated interferon alfa-2b (ViraferonPeg®) 02/02 Schering-Plough Ltd Restricted Full submission
pegylated liposomal doxorubicin (Caelyx) 503/08 Schering-Plough Ltd Not Recommended Full submission
Pegylated liposomal doxorubicin (Caelyx®) 84/03 Schering-Plough Ltd Not Recommended Full submission
pegylated liposomal doxorubicin in combination with boretezomib (Caelyx plus Velcade) 503/08 Schering-Plough Ltd Not Recommended Resubmission
pembrolizumab (Keytruda) 1204/17 MSD Restricted Full submission
pembrolizumab (Keytruda) 1086/15 MSD Accepted Full submission
pembrolizumab (Keytruda) 1087/15 MSD Not Recommended Resubmission
pembrolizumab (Keytruda) 1239/17 MSD Restricted Full submission
pembrolizumab (Keytruda) 1087/15 MSD Not Recommended Full submission
pembrolizumab (Keytruda) UC 1291/18 MSD Restricted Full submission
Pemetrexed (Alimta) 268/06 Eli Lilly and Company Ltd Not Recommended Non submission
pemetrexed (Alimta) 342/07 Eli Lilly and Company Ltd Not Recommended Resubmission
pemetrexed (Alimta) 342/07 Eli Lilly and Company Ltd Restricted Resubmission
pemetrexed (Alimta) 531/09 Eli Lilly and Company Ltd Full submission
pemetrexed (Alimta) 531/09 Eli Lilly and Company Ltd Not Recommended Resubmission
pemetrexed (Alimta) 531/09 Eli Lilly and Company Ltd Restricted Resubmission
pemetrexed (Alimta) 642/10 Eli Lilly and Company Ltd Not Recommended Full submission
pemetrexed (Alimta) 770/12 Eli Lilly and Company Ltd Not Recommended Non submission
pemetrexed (Alimta) 770/12 Eli Lilly and Company Ltd Accepted Full submission
Pemetrexed 500mg infusion (Alimta®) 192/05 Eli Lilly and Company Ltd Superseded Full submission
pemetrexed, 500mg, powder for reconstitution (Alimta) 342/07 Eli Lilly and Company Ltd Not Recommended Full submission
pertuzumab (Perjeta) 1121/16 Roche Not Recommended Full submission
pertuzumab (Perjeta) 897/13 Roche Not Recommended Full submission
pertuzumab (Perjeta) 897/13 Roche Not Recommended Resubmission
pertuzumab (Perjeta) 897/13 Roche Not Recommended Resubmission
pertuzumab (Perjeta) 1121/16 Roche Not Recommended Resubmission
pixantrone (Pixuvri) 1138/16 CTI Life Sciences Ltd Not Recommended Non submission
pomalidomide (Imnovid) 972/14 Celgene Ltd Not Recommended Full submission
pomalidomide (Imnovid) 972/14 Celgene Ltd Accepted Resubmission